In this randomized trial, the authors demonstrated that stage IV or recurrent NSCLC (not previously treated with chemotherapy and with a tumor PD-L1 expression level of less than 1%) who have more than 10 nonsynonymous mutations per megabase have a 42.6% progression free survival at 1 year [17]. The gene discussed is CD274; the disease is neoplasm.